Abstracts Archive - Page 241 of 1683 - ATC Abstracts

2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Matas⁸, A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Childrens Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO, ⁸U Minnesota, Minneapolis, MN
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…
2021 American Transplant Congress
Assessing the Impact of Acute Major Adverse Kidney Events on Clinical Outcomes in Heart Transplant Recipients
J. E. Kelly¹, C. Perez¹, D. Taber¹, R. J. Tedford², B. McMahon², S. Alzaidi¹, H. B. Meadows¹
¹Pharmacy, MUSC Health, Charleston, SC, ²Medicine, MUSC Health, Charleston, SC
*Purpose: The purpose of this study was to elucidate contributors to the Major Adverse Kidney Events at 30 days (MAKE-30) outcome in heart transplant recipients…
2021 American Transplant Congress
Acute Dialysis, Mortality and Renal Failure After Heart Alone Transplant by Egfr and Dialysis Requirement in the United States
M. Aljuhani¹, T. Alexy¹, S. Jackson², C. Martin¹, R. Kandaswamy³, S. Riad¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: We examined the early acute dialysis, 90-day mortality and one-year ESRD among OHT recipients by eGFR and dialysis requirement before transplantation.*Methods: Utilizing the SRTR…
2021 American Transplant Congress
Kidney Transplantation Alone in Patients with Compensated Cirrhosis: A Multicenter Study
A. Kassem¹, S. Asrani¹, S. W. Biggins², Y. Darwish¹, M. Nadim³, B. Fischbach¹, T. Fong³
¹Baylor University Medical Center at Dallas, Dallas, TX, ²University of Washington, Seattle, WA, ³USC - Keck, Los Angeles, CA
*Purpose: Patients undergoing kidney transplant (KTA) often have risk factors for liver disease including viral hepatitis and non-alcoholic fatty liver disease (NAFLD). Recent European Association…
2021 American Transplant Congress
Impact of Cypa5 Status on the Clinical and Financial Outcomes of Kidney Transplant
J. Obayemi¹, B. Keating², K. Lentine³, M. Schnitzler³, H. Xiao³, V. Dharnidharka⁴, D. Axelrod⁵
¹Univ of Michigan, Ann Arbor, MI, ²Univ of Pennsylvania, Philadelphia, PA, ³Saint Louis Univ, Saint Louis, MO, ⁴Washington Univ, Seattle, WA, ⁵Univ of Iowa, Iowa City, IA
*Purpose: Pharmacogenetic profiling of transplant recipients has demonstrated marked variation in the metabolism of immunosuppressive medications, particularly tacrolimus. Patients of African ancestry have been found…
2021 American Transplant Congress
ABCC2 Haplotypes Associations to Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
K. Tornatore¹, D. Brazeau², C. Meaney³, J. Consiglio⁴, A. Gundroo⁵, S. Chang⁶, G. Wilding⁴, L. Cooper³
¹Pharmacy Practice, School of Pharmacy; University at Buffalo- SUNY, Buffalo, NY, ²Pharmacy Practice, Marshall University, Huntington, WV, ³Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ⁴Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ⁵Medicine, School of Medicine; Ohio State University, Columbus, OH, ⁶Medicine, School of Medicine; University at Buffalo, Buffalo, NY
*Purpose: Mycophenolic acid (MPA), exhibits interpatient pharmacokinetic (PK) variability attributed to enterohepatic circulation of the glucuronide metabolite (MPAG) to MPA. This is mediated by multidrug…
2021 American Transplant Congress
Posttransplant Malignancy in HIV+ Kidney Transplant Recipients
D. Sawinski¹, R. Fitzsimmons¹, J. Locke², J. Trofe-Clark¹, B. Shelton², P. Reese¹, E. Blumberg¹
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Alabama at Birmingham, Birmingham, AL
*Purpose: Kidney transplant recipients and people living with HIV are both at increased risk for malignancy, including cancers that are virally-mediated. Despite the recognition of…
2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
N. Singh¹, T. Le¹, M. S. Naseer¹, S. Asmil¹, A. Palermini¹, A. Qamar¹, R. Chand¹, S. Tandukar¹, D. Aultman², H. Shokouh-Amiri², G. Zibari²
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, ²Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
2021 American Transplant Congress
Successful Outcomes from Selected Akin3 Donors Requiring Renal Replacement: Avenue for Increase in Organ Utilization
P. Budhiraja¹, R. L. Heilman¹, M. L. Smith², H. A. Khamash¹, L. Kodali¹, A. A. Moss³, A. K. Mathur³, C. Jadlowiec³, K. S. Reddy³
¹Medicine, Mayo Clinic, Phoenix, AZ, ²Pathology, Mayo Clinic, Phoenix, AZ, ³Surgery, Mayo Clinic, Phoenix, AZ
*Purpose: Our aim was to determine outcomes with transplanting kidneys from deceased donors with severe acute kidney injury requiring acute renal replacement therapy.*Methods: We included…
2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
A. Demirag¹, P. L. Lobo², J. Oberholzer¹, A. Kumar², B. Rawashdeh¹, S. L. Lennon¹, H. N. Guvener Demirag¹, A. Doyle², J. Geystone³, K. L. Brayman¹
¹Transplantation, University of Virginia Medical Center, Charlottesville, VA, ²Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, ³Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…